LGVN: Positive Test Results Highlight Quarterly Results
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
110 Views
LGVN: Financial Update Highlights Successes
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
177 Views
LGVN: Alzheimer's Drug on a Roll with FDA
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
323 Views
LGVN: Alzheimer's Drug on a Roll with FDA
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
154 Views
LGVN: Focus and Cost Controls Improve Outlook
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...
69 Views